Longevity & AgingCRISPR Startup Gets $25M to Target Lp(a) and Triglycerides With One-Time Gene Edits
Scribe Therapeutics has received over $25 million from California's regenerative medicine institute to push two CRISPR gene-editing programs closer to human trials. The first, STX-1200, targets a gene responsible for elevated lipoprotein(a) — a stubborn cardiovascular risk factor that diet and most drugs cannot easily lower. The second, STX-1400, targets a gene linked to dangerously high triglycerides and a painful, life-threatening condition called acute pancreatitis. Both programs aim to deliver a single treatment that permanently corrects the underlying genetic problem. This approach differs from daily medications because the edit is designed to last a lifetime. The funding comes through California's CIRM preclinical program, which bridges lab discoveries to first-in-human studies.
